Polyrizon Pharmaceuticals (PNY) announced a strategic partnership with Clearmind Pharmaceuticals to co-develop and commercialize intranasal monoclonal antibody therapies for central nervous system disorders. The collaboration focuses on advancing CLEARMIND-101, an investigational therapy for Alzheimer's disease, into Phase III trials. The agreement is expected to strengthen PNY's pipeline and provide a clear path to potential commercialization by 2027. Financial terms were not disclosed, but the combined entity plans to leverage shared R&D costs and distribution capabilities.

SPX Technologies (SPX) announced the acquisition of Crawford United, a specialty materials and components company, in a deal valued at $300 million. The transaction is expected to be completed by March 31, 2026, subject to regulatory approvals and due diligence. The acquisition expands SPX's footprint in the industrial and energy sectors, enhancing its capabilities in fluid management and filtration technologies. Terms of the agreement include a combination of cash and stock to be finalized in the coming weeks.

Roivant Sciences (RIVX) surged 17% in premarket trading on February 07, 2026, following the announcement of positive results from its Phase 2 study of brepocitinib, a dual PI3K/mTOR inhibitor, in combination with pembrolizumab for treating advanced melanoma. The study met its primary endpoint, showing a statistically significant improvement in progression-free survival.

The company reported that 56% of patients treated with brepocitinib plus pembrolizumab achieved disease control at 12 weeks, compared to 35% with pembrolizumab alone. Roivant plans to file a New Drug Application in the first half of 2026 and is evaluating additional combination regimens.

Regency Centers (RCI) will hold its Q4 2025 earnings conference call at 11:00 AM Eastern Time on February 25, 2026. The call is open to investors and analysts and will review fourth-quarter results, including revenue, operating income, and same-store sales performance. Management will address guidance for 2026, recent leasing activity, and capital expenditures. The live webcast will be available on the company’s investor relations page, with a replay accessible via the same platform.

The Dow Jones Industrial Average closed at 50,115.67 on Friday, reaching 50,000 for the first time in history, up 1,206.95 points or 2.5%. The milestone followed a volatile week that included a selloff in software stocks and a sharp bitcoin decline, before investors rotated back to blue-chip names like Nvidia (NVDA), Caterpillar (CAT), 3M (MMM), Amgen (AMGN), and Goldman Sachs (GS).

The Dow’s biggest percentage gain since May 2025, it marked its fifth record close of 2026. The S&P 500 (SPX) and Nasdaq Composite (COMP) ended higher on the day, with gains of 2% and 2.2% respectively, while the tech sector posted a weekly loss of 3% despite strong intraday gains.

Strategists note the milestone may reinforce expectations for further gains in U.S. equities, though broader indices provide a more complete view. Wells Fargo Investment Institute raised its 2026 GDP growth forecast to 2.9%.

Bitcoin BTCUSD fell to below $70,000 on Feb 7, 2026, amid a full-bore winter likely to last more than a year, according to Bitwise’s Matt Hougan. The decline follows a peak above $126,000 in October 2025 and echoes the 2022 bear after the 2021 bull.

Crypto-collateralized lending, a volatile but growing market, reached $73.6B in November, per Galaxy Research, with Q3 DeFi loans hitting $41B, up about 55% from the prior quarter. Platforms like Coinbase, Binance, and Firefish allow loans of stablecoins or yield using BTC or ETH collateral, often with LTVs of 50%–75%.

Ultra-high-net-worth borrowers and 401(k) alternatives are increasingly using crypto as collateral, despite risks of prolonged price weakness and leverage-driven drawdowns. Hougan warns the winter began in January 2025 and could persist through 2026, with those who borrowed against BTC facing the steepest declines.

Affirm (AFRM) announced a partnership with Virgin Media O2 to launch a flexible financing program in the United Kingdom, effective February 15, 2026. The initiative aims to provide consumers with accessible, low-interest payment options for eligible purchases, supporting a broader range of merchants.

Key details include a pilot program launching in selected regions in early 2026, with plans to expand nationwide by the end of 2026. Affirm reported the program is expected to serve an initial customer base of 500,000 users, leveraging Virgin Media O2's extensive retail and telecom distribution channels.

Carlyle Group (CG) reported Q4 net income of $287.6 million, up 14.3% from $251.2 million in the same period of 2025, driven by strong performance in its infrastructure and private equity divisions. The company posted revenue of $1.89 billion, a 7.8% increase from $1.76 billion in Q4 2025. Earnings per share rose to $1.12, up from $0.98 in the prior-year period. The stock was 3.7% higher in pre-market trading on the news, reflecting continued confidence in the company's strategic direction and execution.

Image Systems Inc. (IMGI) reported a wider loss in Q4 ended December 31, 2025, with net income down to -$12.5 million, versus -$8.7 million in the same period of the prior year, reflecting lower-than-expected demand and supply chain disruptions. The company announced a no-dividend policy for 2026, citing continued earnings pressure. Shares of IMGI fell 6.2% to $14.85 in after-hours trading on February 7, 2026, following the release of the results.

Abbott Laboratories (ABT) released positive 12-month outcomes from its VOLT-AF IDE study evaluating the novel dual-chamber pacemaker. The results, published on February 7, 2026, indicate a significant reduction in heart failure hospitalizations and improved quality of life for patients with heart failure and reduced ejection fraction.

Key findings include a 32% lower risk of hospitalization for heart failure and a 28% reduction in heart-related readmissions. The study enrolled 1,200 patients across 50 centers and followed them for 12 months. The findings support the device's potential to become a standard treatment option in Abbott's evolving cardiovascular portfolio.

The S&P 500 is expected to regain some ground in early February as stabilizing Fed policy and reduced volatility lift investor confidence. With the index down 2.3% in the preceding session, traders are weighing a potential pullback of 0.5% to 1.0% by Feb 10, based on overnight ECB comments and a slight easing in Treasury yields.

Supporting context: The Federal Open Market Committee left rates unchanged at 5.25%-5.50% in December, signaling policy stability. The Fed's latest statement suggested a balanced approach to tapering, with no immediate indication of rate hikes. Meanwhile, the yield on the 10-year Treasury note eased to 4.38% from 4.42% in the prior session, supporting equities.

Tharimmune (NASDAQ:THAR) announced on February 7, 2026, the appointment of Michael Radkowski as Chief Operating Officer and the designation of Dr. John Wendland as Chairman of the Board. The leadership changes follow the company's recent strategic pivot to accelerate clinical trials and expand its pipeline of immuno-oncology therapies. Radkowski, previously vice president of operations, will oversee day-to-day operations and resource allocation, while Wendland will provide strategic direction and board oversight. The company cited the changes as a step to strengthen its executive team and improve execution efficiency.

TMX Group Inc. (TSE: TMX) reported a wider net loss in Q4 2025, ending the year with a loss of CAD 117.9 million, up from CAD 69.2 million in Q3 2025. The decline followed lower trading volume and FX volatility, with the firm noting a CAD 12.8 million non-cash impairment of goodwill and other intangible assets in the period.

Revenue for the quarter totaled CAD 2.23 billion, a 3.4% year-over-year decline, reflecting reduced market activity and ongoing economic headwinds. The company attributed the results to continued weakness in fixed-income, currencies, and foreign exchange markets, with trading and clearing volumes down 8.2% year-over-year.

The U.S. Food and Drug Administration approved a label update for Yescarta (axicabtagene ciloleucel), a CAR-T therapy from Kite Pharma (KITE). The change expands indications to includeregorafenib-refractory or -resistant gastrointestinal stromal tumors (GIST), adding treatment options for a rare and aggressive cancer subtype.

The FDA's decision reflects a review of clinical trials that demonstrated the therapy's safety and efficacy in this new population. The updated label is effective immediately, enabling earlier approval and broader use of Yescarta in GIST cases where standard treatments have failed.

The U.S. President signed an executive order on February 6, 2026, to realign the prioritization of arms sales, favoring countries with high defense spending and strategic importance in key regions.

The order, titled "America First Arms Transfer Strategy," shifts the approach to prioritize sales to partners who are investing heavily in defense and play critical roles in regional security. It emphasizes leveraging foreign procurement to expand domestic production capacity while not designating specific countries.

Under the new policy, the Departments of Defense, State, and Commerce will establish a prioritized platform and systems directory and identify sale opportunities aligned with the strategy. The order streamlines procedures, including strengthening end-use controls and reviewing third-party transfers, to reduce delays and enhance transparency.

This marks a departure from decades of a "first come, first served" approach, which often led to production backlogs and delivery delays. The administration aims to balance national security with domestic industrial revitalization.

The Carlyle Group Inc. (CG) reported fourth-quarter revenue of $1.1 billion, up 11% from $1.0 billion in the same period of 2025, and net income of $187 million, a 9% increase from $171 million in Q4 2025. The results reflect stronger demand in its private equity and real estate investment management segments, with adjusted EBITDA rising to $315 million for the quarter. CEO James P. Breyfogle said the growth is driven by execution of the company's strategic initiatives and continued diversification of its portfolio.

South Korean crypto exchange Bithumb, which mistakenly distributed over $40 billion worth of Bitcoin on February 5, 2026, announced it will reimburse customers who sold in panic to cover their losses and award an additional 10% bonus. The error—keying in Bitcoin instead of KRW for a promotion—resulted in 620,000 BTC being distributed to 695 users. The exchange halted and retrieved 99.7% of the coins within minutes. Customer losses are estimated at about 1 billion KRW as of 4 p.m. February 7, with Bithumb using corporate assets to restore balances.

On Bithumb, prices briefly fell 17% to about $55,400 and volume spiked during the incident. CEO Lee Jae-won apologized, acknowledging stability and integrity failures. Regulators convened an emergency inspection meeting. Global crypto remains volatile following October’s liquidations, with Bitcoin near $68,000 as of Saturday morning.

TheCAC 40 closed roughly flat at 6,320.56 points, reversing a early session decline after Vinci SA (VNI.PA) surged 2.8% on strong fourth-quarter results. Vinci reported revenue of €2.49 billion, up 7.2% year-over-year, and EPS of €0.46, reflecting higher-than-expected project completions. The broader index was pressured by energy and materials laggards, while industrials and utilities posted gains. The FTSE 100 opened 0.6% higher in London on the heels of Vinci's positive momentum.

Broadridge (BDG) announced on February 7, 2026, the acquisition of CQG (CQ) for $1.2 billion in stock, effective March 31, 2026. The deal expands Broadridge's global derivatives trading and risk management capabilities, enhancing its footprint in institutional markets. Financial terms include an aggregate cash consideration of $250 million and earn-outs tied to post-acquisition revenue and EBITDA milestones. The integration is expected to strengthen client offerings and broaden market reach, with no immediate impact on Broadridge's stock price.

Centene Corporation (CNC) reported fourth-quarter results topping estimates and guided for full-year 2026 adjusted earnings per share above the average analyst forecast. For Q4 2025, revenue fell 2.3% to $3.74 billion, while operating income declined 12.4% to $295 million. The company attributed the decline to lower insurance premiums and a higher claims ratio. Adjusted EPS for Q4 was $0.66, exceeding the $0.63 median estimate. For FY2026, management guided adjusted EPS of $2.45-$2.55, above the $2.35 average forecast.